Fortrea vs Medpace
FTRE and MEDP side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FTRE and MEDP compare
Medpace is the larger company, worth 9.4 times as much as Fortrea ($18.3B against $1.9B).
Medpace grew revenue faster over the last twelve months (20.4% versus −3.4% for Fortrea).
Medpace keeps more of each dollar of sales as profit, with a net margin of 18.2% compared with −2.6% at Fortrea.
Medpace scores higher on the StockData Score (14 against 4 for Fortrea), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FTRE | MEDP |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $18.3B |
| Share price | $20.20 | $653.94 |
| Change, 1 year | 78.1% | 9.4% |
| Change, 5 years | – | 188% |
| Beta (5Y) | 1.46 | 1.39 |
| Employees | 14K | 6,200 |
| StockData Score | ||
| Total score | 4 | 14 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 36.3× |
| P/S | 0.7× (better) | 6.4× |
| P/B | 3.7× (better) | 31.3× |
| EV/EBITDA | 30.4× | 29.0× (better) |
| P/FCF | 11.5× (better) | 27.4× |
| PEG | – | 1.29 |
| FCF yield | 8.7% (better) | 3.6% |
| Fair value | $12.43 | $446.74 |
| Margin of safety | −62.5% | −46.4% (better) |
| Growth | ||
| Revenue growth (TTM) | −3.4% | 20.4% (better) |
| Revenue growth, 5Y average | – | 22.3% |
| Net income growth (TTM) | – | 19.6% |
| EPS growth (TTM) | – | 26.1% |
| EPS growth, 5Y average | – | 31.8% |
| Profitability | ||
| Gross margin | 20.0% | – |
| Operating margin | 0.48% | 21.4% (better) |
| Net margin | −2.6% | 18.2% (better) |
| FCF margin | 6.3% | 23.5% (better) |
| Return on equity | −12.3% | 118% (better) |
| Return on invested capital | 0.69% | – |
| Financial health | ||
| Debt / equity | 1.98 (better) | 0.00 |
| Net debt / EBITDA | 9.12 | – |
| Current ratio | 0.97 (better) | 0.83 |
| Altman Z-score | 0.78 | 8.13 (better) |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 1.6% |
| Shareholder yield | 0.00% | 1.6% (better) |
| Ownership | ||
| Held by institutions | 104% | 88.3% |
| Held by insiders | 3.9% | 20.0% |
| Insider net buying, 12 months | −$4.7M (better) | −$262M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 9.2% | 6.2% |
Go deeper
- FTRE stock overview
- FTRE income statement
- FTRE valuation and score
- MEDP stock overview
- MEDP income statement
- MEDP valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.